Key statistics
As of last trade Supernus Pharmaceuticals Inc (SUPN:NMQ) traded at 32.39, -8.61% below its 52-week high of 35.44, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.99 |
---|---|
High | 32.40 |
Low | 31.87 |
Bid | 32.33 |
Offer | 32.42 |
Previous close | 32.06 |
Average volume | 293.81k |
---|---|
Shares outstanding | 55.11m |
Free float | 52.33m |
P/E (TTM) | 362.96 |
Market cap | 1.77bn USD |
EPS (TTM) | 0.0883 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 19:13 BST.
More ▼
Announcements
- Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Announces Second Quarter 2024 Financial Results
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
- Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
More ▼